Search publications

Publications

  • Cereijo R, Villarroya-Terrade J and Villarroya-Gombau F.

    Non-sympathetic control of brown adipose tissue.

    International journal of obesity supplements . 5(Suppl 1): .

    [doi:10.1038/ijosup.2015.10]

  • Sheedfar F, Vermeer M, Pazienza V, Villarroya-Terrade J, Rappa F, Cappello F, Mazzoccoli G, Villarroya-Gombau F, van der Molen H, Hofker MH, Koonen DP and Vinciguerra M.

    Genetic ablation of macrohistone H2A1 leads to increased leanness, glucose tolerance and energy expenditure in mice fed a high-fat diet.

    INTERNATIONAL JOURNAL OF OBESITY . 39(2): 331-338. Number of citations: 19

    [doi:10.1038/ijo.2014.91]

  • Domingo P, Lamarca MK, Gallego-Escuredo JM, Torres F, Domingo JC, Villarroya-Terrade J, Gutierrez Mdel M, Mateo MG, Vidal F, Villarroya-Gombau F and Giralt M.

    Circulating fibroblast growth factor 23 (FGF23) levels are associated with metabolic disturbances and fat distribution but not cardiovascular risk in HIV-infected patients.

    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY . 70(6): 1825-1832. Number of citations: 11

    [doi:10.1093/jac/dkv027]

  • Villarroya-Terrade J, Flachs P, Redondo-Angulo I, Giralt M, Medrikova D, Villarroya-Gombau F, Kopecky J and Planavila A.

    Fibroblast growth factor-21 and the beneficial effects of long-chain n-3 polyunsaturated fatty acids.

    Lipids . 49(11): 1081-1089. Number of citations: 20

    [doi:10.1007/s11745-014-3948-x]

  • Domingo P, Gutierrez Mdel M, Gallego-Escuredo JM, Torres F, Mateo MG, Villarroya-Terrade J, Lamarca K, Domingo JC, Vidal F, Villarroya-Gombau F and Giralt M.

    A 48-week study of fat molecular alterations in HIV naive patients starting tenofovir/emtricitabine with lopinavir/ritonavir or efavirenz.

    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES . 66(5): 457-465. Number of citations: 13

    [doi:10.1097/QAI.0000000000000205]

  • Gallego-Escuredo JM, Villarroya-Terrade J, Domingo P, Targarona EM, Alegre M, Domingo JC, Villarroya-Gombau F and Giralt M.

    Differentially altered molecular signature of visceral adipose tissue in HIV-1-associated lipodystrophy.

    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES . 64(2): 142-148. Number of citations: 27

    [doi:10.1097/QAI.0b013e31829bdb67]

  • Gallego-Escuredo JM, Domingo P, Fontdevila J, Villarroya-Terrade J, Domingo JC, Martinez E, Giralt M and Villarroya-Gombau F.

    Hypertrophied facial fat in an HIV-1-infected patient after autologous transplantation from 'buffalo hump' retains a partial brown-fat-like molecular signature.

    ANTIVIRAL THERAPY . 18(4): 635-639. Number of citations: 3

    [doi:10.3851/IMP2528]

  • Villarroya-Terrade J, Dorado B, Vilà MR, Garcia-Arumí E, Domingo P, Giralt M, Hirano M and Villarroya-Gombau F.

    Thymidine kinase 2 deficiency-induced mitochondrial DNA depletion causes abnormal development of adipose tissues and adipokine levels in mice.

    PLoS One . 6(12): . Number of citations: 18

    [doi:10.1371/journal.pone.0029691]

  • Villarroya-Terrade J, Giralt M and Villarroya-Gombau F.

    Mitochondrial DNA: an up-and-coming actor in white adipose tissue pathophysiology.

    Obesity . 17(10): 1814-1820. Number of citations: 31

    [doi:10.1038/oby.2009.152]